Immuron Limited IMC.AX Stock
Immuron Limited Price Chart
Immuron Limited IMC.AX Financial and Trading Overview
Immuron Limited stock price | 0.11 AUD |
Previous Close | 0.08 AUD |
Open | 0.08 AUD |
Bid | 0.08 AUD x 0 |
Ask | 0.08 AUD x 0 |
Day's Range | 0.08 - 0.08 AUD |
52 Week Range | 0.07 - 0.11 AUD |
Volume | 212.02K AUD |
Avg. Volume | 132.21K AUD |
Market Cap | 17.54M AUD |
Beta (5Y Monthly) | 1.293103 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.02 AUD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
IMC.AX Valuation Measures
Enterprise Value | -727216 AUD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 15.690883 |
Price/Book (mrq) | 0.827957 |
Enterprise Value/Revenue | -0.651 |
Enterprise Value/EBITDA | 0.237 |
Trading Information
Immuron Limited Stock Price History
Beta (5Y Monthly) | 1.293103 |
52-Week Change | -12.22% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.11 AUD |
52 Week Low | 0.07 AUD |
50-Day Moving Average | 0.08 AUD |
200-Day Moving Average | 0.08 AUD |
IMC.AX Share Statistics
Avg. Volume (3 month) | 132.21K AUD |
Avg. Daily Volume (10-Days) | 90.74K AUD |
Shares Outstanding | 227.8M |
Float | 190.57M |
Short Ratio | N/A |
% Held by Insiders | 18.08% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:40 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | -270.26% |
Operating Margin (ttm) | -275.20% |
Gross Margin | 90.20% |
EBITDA Margin | -274.80% |
Management Effectiveness
Return on Assets (ttm) | -7.93% |
Return on Equity (ttm) | -13.29% |
Income Statement
Revenue (ttm) | 1.12M AUD |
Revenue Per Share (ttm) | 0.005 AUD |
Quarterly Revenue Growth (yoy) | 152.69% |
Gross Profit (ttm) | 523.5K AUD |
EBITDA | -3072019 AUD |
Net Income Avi to Common (ttm) | -3021183 AUD |
Diluted EPS (ttm) | -0.01 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 19.14M AUD |
Total Cash Per Share (mrq) | 0.08 AUD |
Total Debt (mrq) | 192.79K AUD |
Total Debt/Equity (mrq) | 0.91 AUD |
Current Ratio (mrq) | 12.111 |
Book Value Per Share (mrq) | 0.093 |
Cash Flow Statement
Operating Cash Flow (ttm) | -1812637 AUD |
Levered Free Cash Flow (ttm) | -1213996 AUD |
Profile of Immuron Limited
Country | Australia |
State | VIC |
City | Carlton |
Address | 62 Lygon Street |
ZIP | 3053 |
Phone | 61 3 9824 5254 |
Website | https://www.immuron.com.au |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 5 |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Q&A For Immuron Limited Stock
What is a current IMC.AX stock price?
Immuron Limited IMC.AX stock price today per share is 0.11 AUD.
How to purchase Immuron Limited stock?
You can buy IMC.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immuron Limited?
The stock symbol or ticker of Immuron Limited is IMC.AX.
Which industry does the Immuron Limited company belong to?
The Immuron Limited industry is Biotechnology.
How many shares does Immuron Limited have in circulation?
The max supply of Immuron Limited shares is 227.8M.
What is Immuron Limited Price to Earnings Ratio (PE Ratio)?
Immuron Limited PE Ratio is now.
What was Immuron Limited earnings per share over the trailing 12 months (TTM)?
Immuron Limited EPS is -0.02 AUD over the trailing 12 months.
Which sector does the Immuron Limited company belong to?
The Immuron Limited sector is Healthcare.